When is Corcept Therapeutics Incorporated's (CORT) next earnings report?

Corcept Therapeutics Incorporated's next earnings report is expected on July 30, 2026 (19 days away). View CORT's historical earnings reactions and AI-powered earnings trade plan on Trend Edge at https://trendedge.app/asset/CORT

What is Corcept Therapeutics Incorporated's (CORT) market cap?

Corcept Therapeutics Incorporated has a market cap of $10.01B, classifying it as a large-cap Healthcare stock. Trend Edge tracks CORT's institutional ownership (75.6%), insider transactions, and proprietary indicators.

What is CORT's Trend Edge Score?

CORT's current Trend Edge Score is 86.7. The Trend Edge Score is a proprietary technical indicator combining weekly trend strength, momentum, and volume signals into a single value used to rank long position setups across thousands of tracked stocks.

How has CORT historically reacted to earnings?

Over the last 89 earnings events, CORT has averaged a 1.31% return in the week following earnings, with a 52.81% win rate. Best 1-week reaction: +77.78%. Worst: -47.20%. Full earnings reaction breakdown across gap, 1-day, 2-week, and 1-month timeframes available on Trend Edge.

What is the average analyst price target for CORT?

6 Wall Street analysts have an average price target of $88.00 on CORT, implying 4.2% downside from the current price of $91.88.

CORT Stock Analysis — Corcept Therapeutics Incorporated · Founder-Led

Q: Is Corcept Therapeutics Incorporated (CORT) founder-led?

Yes — Corcept Therapeutics Incorporated is founder-led. Current founder leadership: Joseph K. Belanoff (Chief Executive Officer, President and Director). Founder-led companies are tracked separately by Trend Edge as a proprietary indicator.

Trend Edge Setup Score

Trend Edge rates CORT Bullish with a Setup Score of 0, net conviction 47, actionability 0. How the Setup Score works →

Total Setup Score	0
Directional Bias	Bullish
Net Conviction	47
Actionability	0 (extended)

Key signals behind this score

40wk Uptrend — rising+above (sma 60.04 vs px 93.25)
Fresh Trend Turn — 40wk turn 2w+10wk turn 13w · 40wk recapture 8w · ×0.99 extended
80wk Uptrend — rising+above (sma 64.26 vs px 93.25)
200wk Uptrend — rising+above (sma 43.33 vs px 93.25)
Insider Buying — unplanned ≥$50k buy · $5.7M · 1.5 insiders · +0.5 size · +2 position Δ (28%)
Short Squeeze Setup — velZ +1.61 · age 101w×0.45 · 9.53%
Founder-Led — founder/CEO led
Earnings Tailwind — ER in 19.246d · w1 med 1.5% (mag 1/3) · winRate 52.8% (rel 0/3) · n89

About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have… Read full Trend Edge analysis →

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: April 14, 2004
Headquarters: 101 Redwood Shores Parkway, Redwood City, CA, United States, 94065
Website: https://www.corcept.com
Employees: 730

Current Price	$91.88
Market Cap	$10.01B
Float	89.9M
Shares Outstanding	107.4M
P/E (Forward)	113.64
P/E (TTM)	266.43
Price/Sales (TTM)	13.02
vs. Analyst Target	-4.2% to analyst PT
Profit Margin	6.16%
Operating Margin (TTM)	-30.08%
Revenue (TTM)	$769M
Earnings Growth (YoY)	-21.60%
Dividend Rate	None
Analyst Target Price	$88.00 (6 analysts)

Year	Revenue	Net Income	Gross Profit	EBITDA
2020	$354M	$106M	$348M	$130M
2021	$366M	$113M	$361M	$128M
2022	$402M	$101M	$396M	$116M
2023	$482M	$106M	$476M	$126M
2024	$675M	$140M	$664M	$163M
2025	$761M	$99.7M	$748M	$68.4M

Quarter	Revenue	Net Income
Jun 2025	$194M	$35.1M
Sep 2025	$208M	$19.7M
Dec 2025	$202M	$24.3M
Mar 2026	$165M	-$31.2M

Insider Ownership	11.5%
Institutional Ownership	75.6%
Short Float	9.5%
% of All Funds Holding	3.88%
Number of Funds Holding	319

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

Timeframe	SMA	Value	Trend Context
Weekly	10-Week SMA	$74.32	Near-term / short-term trend
Weekly	40-Week SMA	$60.01	Medium-term trend
Weekly	80-Week SMA	$64.24	Cyclical trend (business cycle)
Weekly	200-Week SMA	$43.32	Secular trend (multi-year)
Monthly	10-Month SMA	$59.84	Near-term monthly trend
Monthly	20-Month SMA	$66.67	Medium-term monthly trend
Monthly	40-Month SMA	$48.89	Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price Level	Type	Volume Ratio	Age
$114.00	resistance	1.76x	14 months ago
$23.10	support	1.19x	25 months ago

Timeframe	Avg Return	Median	Win Rate	Best	Worst
Gap	0.48%	0.00%	48.31%	26.68%	-14.16%
1 Day	0.33%	-0.21%	47.19%	24.91%	-14.29%
1 Week	1.31%	1.52%	52.81%	77.78%	-47.20%
2 Weeks	1.59%	2.52%	57.30%	70.00%	-63.94%
1 Month	6.88%	5.53%	62.50%	80.24%	-64.79%

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Month	Avg Return	Win Rate	Samples
Jan	2.1%	50.0%	22
Feb	0.8%	40.9%	22
Mar	14.0%	77.3%	22
Apr	0.6%	54.5%	22
May	2.5%	52.2%	23
Jun	5.3%	47.8%	23
Jul	-0.5%	45.5%	22
Aug	-0.7%	40.9%	22
Sep	6.3%	45.5%	22
Oct	-0.7%	50.0%	22
Nov	1.9%	50.0%	22
Dec	3.0%	40.9%	22

Day-of-Week Tendencies

Day	Avg Return	Win Rate	Samples
Monday	0.27%	49.4%	1047
Tuesday	0.18%	47.9%	1148
Wednesday	0.21%	49.9%	1148
Thursday	0.17%	48.5%	1127
Friday	-0.09%	47.6%	1120

Insider Transactions — Smart Summary

Total insider ownership: 11.5%

Founder-led management: Joseph K. Belanoff (Chief Executive Officer, President and Director)

12-Month Insider Activity Summary

Total Filings	51
Net Value	-$53.8M
Net Shares Change	-216,096
% of Float	-0.2%
C-Suite Filings	44
Clusters Detected	8

Key Insiders

Name	Title	Net Value	Filings	Activity
Mokari Atabak	Chief Financial Officer	-$4.5M	2	N/A
Maduck Sean	President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.	-$4.2M	2	N/A
BAKER G LEONARD JR		+$3.3M	1	1 buy
Guyer William	Chief Development Officer	-$1.8M	2	1 sell
MAHONEY DAVID L		-$1.7M	1	1 sell
Robb Gary Charles	Chief Business Officer	-$336,682.6	1	1 sell
Lyon Joseph Douglas	Chief Accounting & Technology Officer	-$325,000	1	1 sell

Transaction Clusters

Period	Filings	Insiders	Net Value	Seniority
2025-07-14 – 2025-07-21	5	5	-$995,453.422	4 C-suite
2025-08-05 – 2025-08-12	6	5	-$7.1M	5 C-suite
2025-08-26 – 2025-09-04	5	5	-$5.8M	5 C-suite
2025-10-03 – 2025-10-15	5	5	-$6.8M	4 C-suite
2025-11-05 – 2025-11-07	4	4	-$5.7M	4 C-suite
2025-12-03 – 2025-12-03	5	4	-$6.5M	5 C-suite
2026-05-29 – 2026-06-04	6	5	-$10.1M	6 C-suite
2026-06-17 – 2026-06-18	3	3	-$5.0M	1 C-suite

Significant Filings

Date	Insider	Title	Net Value	Price After
2026-05-29	Lyon Joseph Douglas	Chief Accounting & Technology Officer	-$325,000	Transaction at $65.00, now +41.4%
2026-06-18	MAHONEY DAVID L		-$1.7M	Transaction at $84.53, now +8.7%
2026-03-19	BAKER G LEONARD JR		+$3.3M	Transaction at $33.14, now +177.3%
2025-12-03	Guyer William	Chief Development Officer	-$364,070.25	Transaction at $80.90, now +13.6%
2025-08-26	Robb Gary Charles	Chief Business Officer	-$336,682.6	Transaction at $48.77, now +88.4%
2025-08-05	Maduck Sean	President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.	-$2.2M	Transaction at $36.42, now +152.3%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Corcept Therapeutics Incorporated (CORT) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for CORT on Trend Edge →

CORT — Corcept Therapeutics Incorporated

Trend Edge Setup Score

Key signals behind this score

About Corcept Therapeutics Incorporated

Trend Edge Proprietary Indicators

Key Metrics

Financial History

Annual Revenue & Earnings History

Recent Quarterly Revenue & Net Income

Ownership & Float

Current Moving Averages

Volume Shelves — Support & Resistance

Historical Earnings Reactions (89 events)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Day-of-Week Tendencies

Top Institutional Holders

Insider Transactions — Smart Summary

12-Month Insider Activity Summary

Key Insiders

Transaction Clusters

Significant Filings

AI Consult Analysis

CORT — Corcept Therapeutics Incorporated

Trend Edge Setup Score

Key signals behind this score

About Corcept Therapeutics Incorporated

Trend Edge Proprietary Indicators

Key Metrics

Financial History

Annual Revenue & Earnings History

Recent Quarterly Revenue & Net Income

Ownership & Float

Current Moving Averages

Volume Shelves — Support & Resistance

Historical Earnings Reactions (89 events)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Day-of-Week Tendencies

Top Institutional Holders

Insider Transactions — Smart Summary

12-Month Insider Activity Summary

Key Insiders

Transaction Clusters

Significant Filings

AI Consult Analysis

Related Biotechnology Stocks